Project Grant R01HL172871
Award Date
12/15/24
Completion Date
11/30/28
Dollars Obligated
$618K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
This $777,258 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the understanding of heart failure in patients with hypertrophic cardiomyopathy (HCM) through novel cardiac MRI imaging techniques. The principal investigator at the Beth Israel Deaconess Medical Center, Inc. (Bidmc) will leverage advanced cardiac MRI technologies, including diffusion tensor imaging, spectroscopy, and...
This $174,050 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the molecular basis of contractile dysfunction in human dilated cardiomyopathy. The project aims to investigate the role of the myosin super-relaxed state, a key regulator of cardiac muscle contractility, in depressed cardiac function in dilated cardiomyopathy. Specifically, the research will quantify the proportion...
This $194,375 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how changes in the mechanical properties of the extracellular matrix during cardiomyopathy progression affect cardiomyocyte function and phenotype. The research aims to: 1) Determine if cardiomyopathy-driven extracellular matrix remodeling alters myocardial viscoelasticity, and 2) Assess how matrix...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $730,764 Project Grant to Case Western Reserve University to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere structure and function, and link these mechanisms to the development of hypertrophic cardiomyopathy (HCM). The project aims to utilize cryo-electron microscopy, cellular biophysics...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $767,579 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center to conduct research aimed at discovering and defining the effects of rare genetic variants on hypertrophic cardiomyopathy (HCM). The project will leverage data from large biobanks comprising over 1.5 million participants and 5,000 HCM cases to address critical knowledge...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,408,580.00 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary grantee, The Leland Stanford Junior University, will conduct research to determine if activating this pathway can restore contractile function in human-induced pluripotent stem cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The grant, awarded on December 20, 2024, will fund research to establish a new high-throughput system for reclassifying genetic variants associated with hypertrophic cardiomyopathy (HCM) and to determine the role of potential genetic modifiers that influence the severity of HCM caused by pathogenic MYH7 gene...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to uncover effective strategies for mitigating the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The $159,512 award will fund the validation and description of the anti-fibrotic mechanisms of two drug compounds, CGS15943 and AM404, in a mouse model of LMNA-related DCM. The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support a $135,840 multiscale computational and experimental investigation of cardiac contractile dysfunction mechanisms in familial cardiomyopathies. The two-year project, starting on September 1, 2024, will focus on understanding how structural perturbations to the myosin motor protein impact its interaction with actin and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $692,971 to Case Western Reserve University to conduct a collaborative research project aimed at advancing the understanding of genetic mutations in cardiac myosin binding protein C (cMyBP-C) that can lead to hypertrophic cardiomyopathy. The project integrates molecular biology, biophysics,...